MRK · News · 20261031N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-10-31 · Importance 61 · Surprise 92

In the Phase 3 INTerpath-001 trial in resected high-risk melanoma, Merck’s KEYTRUDA combined with Moderna’s personalized mRNA therapy intismeran autogene reduced the risk of recurrence or death by 42% versus KEYTRUDA alone. The combination also reduced the risk of distant metastasis or death by 38%. The therapy uses one-patient-at-a-time manufacturing and individualized neoantigen selection, creating production and cost complexity as it is scaled.

Key facts

• In the Phase 3 INTerpath-001 trial in resected high-risk melanoma, intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% versus KEYTRUDA alone. source
• In the Phase 3 INTerpath-001 trial in resected high-risk melanoma, intismeran autogene plus KEYTRUDA reduced the risk of distant metastasis or death by 38% versus KEYTRUDA alone. source